Transaction Details

  • Coris Bioconcept SRL (subsidiary of 3B BlackBio Dx Ltd) entered definitive agreement to acquire 100% shares of Bilex SRL
  • Acquisition completed on November 18, 2026
  • Bilex SRL owns land and building at Rue Guillaume Fouquet 11, 5032 Gembloux, Belgium where Coris office and manufacturing plant is situated
  • Sellers: Mr. Thierry Leclipteux (50% shareholder) and Mr. Joseph Bertinetti (50% shareholder)
  • Post-acquisition, Bilex SRL becomes subsidiary of Coris Bioconcept SRL

Financial Consideration

  • Cash consideration: €274,817 for 100% shares of Bilex SRL
  • Additional payments: €1.32 million unsecured loan repayment to two shareholders
  • Assumption of Bilex's long-term building loans: €2.11 million payable over remaining 12 years at average interest rate of 1.3%

Target Entity Information

  • Bilex SRL, incorporated in 2014, located at 11, Rue Guillaume Fouquet, 5032 Isnes (Gembloux), Belgium
  • Business: Property ownership (no specific industry classification)
  • Historical rental income: FY2023: €203,500.00; FY2024: €227,319.00; FY2025: €232,267.05
  • Facility details: 6,443 m² land parcel with 2,000 m² building constructed in 2023, includes administrative offices, labs with containment airlocks, temperature and humidity control, 256 solar panels, rainwater collection system

Rationale and Impact

  • Transitions Coris from tenant to owner-occupier of manufacturing facility
  • Eliminates intercompany rental payments, generating immediate net annual savings of €140,000 before depreciation
  • Consolidates Bilex accounts into Coris, simplifying financial statements
  • Future property-related expenses limited to bank interest on building loans (€2.11 million at 1.3%) and depreciation
  • Secures permanent infrastructure for global diagnostic pipeline operations

Regulatory Approvals

  • No governmental or regulatory approvals required for the acquisition
  • Transaction does not qualify as related party transaction
  • Promoter/promoter group has no interest in Bilex SRL

Management Commentary

  • Mr. Sébastien Goenen (CEO - Coris Bioconcept SRL): Acquisition provides long-term control over operating infrastructure, delivers recurring savings, and enables scaling of manufacturing capabilities
  • Mr. Dhirendra Dubey (Founder CEO - 3B BlackBio Dx Limited): Strengthens operational foundation of Coris, optimizes rental outflows, provides long-term certainty over critical operating asset

Company Background

  • 3B BlackBio Dx Limited: Research-driven company developing IVD products under TRUPCR®, TRURAPID®, and TRUNGS® brands focused on oncology and infectious disease diagnostics
  • Coris Bioconcept SRL: Founded 1996, develops/manufactures IVD rapid test kits (lateral flow assays), ISO 13485 certified, distributes to over 60 countries